Abstract:The most well-known pathogenic risk factor for myeloid neoplasms (MN) is clonal hematopoiesis of indeterminate potential (CHIP) . However, MN can develop in CHIP negative individuals, indicating that additional markers of clonal expansion might also be informative. Heteroplasmy, defined as the presence of mitochondrial DNA (mtDNA) mutations in a subset of cellular mtDNA, has been associated with hematological malignancies and could represent a marker of clonal expansion . However, the relationship between heteroplamsy and CHIP, as well as its association with the incidence of MN in the general population is not known. In this study, we explored the association between somatic mtDNA and nuclear DNA (nDNA) mutations (mito-nuclear interaction), its impact on MN incidence, and whether its inclusion to the latest CHIP-based MN prediction algorithm could improve risk stratification in over 440,000 participants in the UK Biobank and Atherosclerosis Risk in Communities (ARIC) studies. We found that heteroplasmy count and heteroplasmic variants predicted to be more deleterious were enriched in individuals with CHIP, particularly in those with significantly expanded clones (VAF ≥20%), with more than one CHIP mutation, and with mutations in the spliceosome machinery. Individuals with both heteroplasmy and CHIP were more likely to develop MN than participants with either entity alone. Furthermore, we found a significant and independent association of predicted pathogenic effect of heteroplasmic variants with incident MN, suggesting a causal role of mtDNA variations in MN pathogenesis, even in the absence of CHIP. Finally, incorporating heteroplasmy into an existing risk score model for MN in individuals with CHIP significantly improved the sensitivity by 13.1% and identified 34.4% more cases in the high-risk group (10-year risk ≥10%). In sum, our findings suggest that heteroplasmy, in addition to being a marker of clonal expansion, may be a causal biomarker of MN development, with clinical utility in the general population.

Association analysis of mitochondrial DNA heteroplasmic variants: methods and application

Presence and transmission of mitochondrial heteroplasmic mutations in human populations of European and African ancestry

Epigenome-wide Association Analysis of Mitochondrial Heteroplasmy Provides Insight into Molecular Mechanisms of Disease

Genetic Landscape of Human Mitochondrial Genome Using Whole-Genome Sequencing.

Longitudinal change in mitochondrial heteroplasmy exhibits positive selection for deleterious variants

Association Studies on mtDNA and Parkinson’s Disease Population Discrimination Using the Statistical Classification

Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms

Evaluating Heteroplasmic Variations of the Mitochondrial Genome from Whole Genome Sequencing Data

Detecting Rare Variants and Heteroplasmy of Mitochondrial DNA from High-Throughput Sequencing in Patients with Coronary Artery Disease

Tissue-specific apparent mtDNA heteroplasmy and its relationship with ageing and mtDNA gene expression

Whole-exome sequencing in 415,422 individuals identifies rare variants associated with mitochondrial DNA copy number

Epigenome-wide association study of mitochondrial genome copy number

Nuclear genetic control of mtDNA copy number and heteroplasmy in humans

Independent impacts of aging on mitochondrial DNA quantity and quality in humans

Single-cell analysis reveals context-dependent, cell-level selection of mtDNA

Association Analysis and Meta-Analysis of Multi-Allelic Variants for Large-Scale Sequence Data

Genetic association study of common mitochondrial variants on body fat mass.

Mitochondrial DNA Sequence Variation is Associated with Free-Living Activity Energy Expenditure in the Elderly.

Association Between Whole Blood-Derived Mitochondrial DNA Copy Number, Low-Density Lipoprotein Cholesterol, and Cardiovascular Disease Risk

Mitochondrial DNA copy number associated dementia risk by somatic mutations and frailty

Prospective of Mitochondrial DNA Variations in Cancer on Genomic Medicine